BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong H, Tang YF, Yao TJ, Chiu J, Leung R, Chan P, Cheung TT, Chan AC, Pang RW, Poon R, Fan ST, Yau T. The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). Oncologist. 2011;16:1721-1728. [PMID: 22135121 DOI: 10.1634/theoncologist.2011-0192] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Liu C, Zhang N. Emerging biotechnological strategies for non-viral antiangiogenic gene therapy. Angiogenesis 2012;15:521-42. [DOI: 10.1007/s10456-012-9295-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Ziogas DC, Papadatos-pastos D, Thillai K, Korantzis I, Chowdhury R, Suddle A, O’grady J, Al-khadimi G, Allen N, Heaton N, Ross PJ, Sarker D. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. European Journal of Gastroenterology & Hepatology 2017;29:48-55. [DOI: 10.1097/meg.0000000000000739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
3 Marta GN, da Fonseca LG, Braghiroli MI, Moura F, Hoff PM, Sabbaga J. Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma. Clinics (Sao Paulo) 2021;76:e2498. [PMID: 33503195 DOI: 10.6061/clinics/2021/e2498] [Reference Citation Analysis]
4 Tew WP, Fleming GF. Treatment of ovarian cancer in the older woman. Gynecologic Oncology 2015;136:136-42. [DOI: 10.1016/j.ygyno.2014.10.028] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
5 Cheung WK, Ho MP, Chou AH. Small cell lung carcinoma mimicking hepatocellular carcinoma with direct invasion into the inferior vena cava and through the right hemidiaphragm in an elderly adult. J Am Geriatr Soc 2014;62:2008-9. [PMID: 25333549 DOI: 10.1111/jgs.13021] [Reference Citation Analysis]
6 He EX, Nie ZS, Zhu MY, Lin HF, Wang L, Lin ZD, Xie XJ, Li MS. Association of alpha fetoprotein levels and presence of parasitical blood vessels with response to TACE in patients with advanced liver cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(20): 1931-1938 [DOI: 10.11569/wcjd.v21.i20.1931] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Cao G, Li X, Qin C, Li J. Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis. Med Sci Monit. 2015;21:3144-3151. [PMID: 26476711 DOI: 10.12659/msm.894617] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
8 Hori M, Tanaka M, Ando E, Sakata M, Shimose S, Ohno M, Yutani S, Kuraoka K, Kuromatsu R, Sumie S, Sata M. Long-term outcome of elderly patients (75 years or older) with hepatocellular carcinoma. Hepatol Res 2014;44:975-82. [PMID: 24256493 DOI: 10.1111/hepr.12279] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
9 Meriggi F, Graffeo M. Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. Cancers (Basel) 2021;13:584. [PMID: 33540870 DOI: 10.3390/cancers13030584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cohen MJ, Levy I, Barak O, Bloom AI, Fernández-Ruiz M, Di Maio M, Perrone F, Poon RT, Shouval D, Yau T. Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database. Liver Int. 2014;34:1109-1117. [PMID: 24512125 DOI: 10.1111/liv.12486] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
11 Montella L, Addeo R, Cennamo G, Vincenzi B, Palmieri R, Sperlongano P, Sperlongano R, Iodice P, Russo P, Del Prete S. Sorafenib in elderly patients with advanced hepatocellular carcinoma: A case series. Oncology. 2013;84:265-272. [PMID: 23428832 DOI: 10.1159/000345558] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
12 de Stefano G, Iodice V, Farella N. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report. J Gastrointest Cancer 2015;46:430-3. [PMID: 25894635 DOI: 10.1007/s12029-015-9720-5] [Reference Citation Analysis]
13 Germano D, Tinessa V, Barletta E, Cannella L, Daniele B. Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib. Drugs Aging 2013;30:887-92. [PMID: 24097332 DOI: 10.1007/s40266-013-0124-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
14 Di Costanzo GG, Tortora R, De Luca M, Galeota Lanza A, Lampasi F, Tartaglione MT, Picciotto FP, Imparato M, Mattera S, Cordone G. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Med Oncol. 2013;30:446. [PMID: 23307255 DOI: 10.1007/s12032-012-0446-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
15 Zhao GS, Li C, Liu Y, Ren ZZ, Yuan XL, Zhou J, Zhang YW, Zhang M. 350-560 μm gelatin sponge particles combined with transcatheter arterial chemoembolization for the treatment of elderly hepatocellular carcinoma: The safety and efficacy. Medicine (Baltimore) 2017;96:e6629. [PMID: 28422858 DOI: 10.1097/MD.0000000000006629] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
16 Cohen MJ, Bloom AI, Barak O, Klimov A, Nesher T, Shouval D, Levi I, Shibolet O. Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma. World J Gastroenterol 2013; 19(16): 2521-2528 [PMID: 23674854 DOI: 10.3748/wjg.v19.i16.2521] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
17 Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013;4:635-43. [PMID: 24155775 DOI: 10.7150/jca.7279] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]
18 Nemoto T, Matsuda H, Nosaka T, Saito Y, Ozaki Y, Hayama R, Naito T, Takahashi K, Ofuji K, Ohtani M, Hiramatsu K, Suto H, Nakamoto Y. Comparison of hepatic arterial infusion chemotherapy and sorafenib in elderly patients with advanced hepatocellular carcinoma: A case series. Mol Clin Oncol 2014;2:1028-34. [PMID: 25279193 DOI: 10.3892/mco.2014.371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Cheung TT, Fan ST, Chu FS, Jenkins CR, Chok KS, Tsang SH, Dai WC, Chan AC, Chan SC, Yau TC, Poon RT, Lo CM. Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma. HPB (Oxford) 2013;15:567-73. [PMID: 23458602 DOI: 10.1111/hpb.12025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
20 Borzio M, Dionigi E, Parisi G, Raguzzi I, Sacco R. Management of hepatocellular carcinoma in the elderly. World J Hepatol 2015; 7(11): 1521-1529 [PMID: 26085911 DOI: 10.4254/wjh.v7.i11.1521] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
21 Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Costanzo FD, Marra F. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20(3): 786-794 [PMID: 24574751 DOI: 10.3748/wjg.v20.i3.786] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
22 Santini D, Addeo R, Vincenzi B, Calvieri A, Montella L, Silletta M, Caraglia M, Vespasiani U, Picardi A, Del Prete S. Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. Expert Rev Anticancer Ther. 2012;12:1283-1288. [PMID: 23094801 DOI: 10.1586/era.12.102] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
23 Jo M, Yasui K, Kirishima T, Shima T, Niimi T, Katayama T, Mori T, Funaki J, Sumida Y, Fujii H, Takami S, Kimura H, Mitsumoto Y, Minami M, Yamaguchi K, Yoshinami N, Mizuno M, Sendo R, Tanaka S, Shintani H, Kagawa K, Okanoue T, Itoh Y. Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma. Hepatol Res. 2014;44:1329-1338. [PMID: 24528772 DOI: 10.1111/hepr.12308] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
24 Tew WP. Ovarian cancer in the older woman. J Geriatr Oncol 2016;7:354-61. [PMID: 27499341 DOI: 10.1016/j.jgo.2016.07.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 6.5] [Reference Citation Analysis]
25 Edeline J, Crouzet L, Le Sourd S, Larible C, Brunot A, Le Roy F, Cattenoz C, Latournerie M, Gédouin D, Guillygomarc'h A, Boucher E. Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. Cancer Chemother Pharmacol 2015;75:215-9. [PMID: 25477009 DOI: 10.1007/s00280-014-2645-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
26 Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: The present and the future. World J Hepatol 2017; 9(21): 907-920 [PMID: 28824742 DOI: 10.4254/wjh.v9.i21.907] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 14.4] [Reference Citation Analysis]
27 Cammarota A, D'Alessio A, Pressiani T, Rimassa L, Personeni N. Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs Aging 2021;38:579-91. [PMID: 34152589 DOI: 10.1007/s40266-021-00871-5] [Reference Citation Analysis]
28 Bolondi L, Craxi A, Trevisani F, Daniele B, Di Costanzo GG, Fagiuoli S, Cammà C, Bruzzi P, Danesi R, Spandonaro F. Refining sorafenib therapy: lessons from clinical practice. Future Oncol. 2015;11:449-465. [PMID: 25360997 DOI: 10.2217/fon.14.261] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
29 Thomsen M, Clarke S, Vitetta L. The role of adjuvant probiotics to attenuate intestinal inflammatory responses due to cancer treatments. Benef Microbes 2018;9:899-916. [PMID: 30232908 DOI: 10.3920/BM2017.0172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
30 Kinoshita A, Koike K, Nishino H. Clinical features and prognosis of elderly patients with hepatocellular carcinoma not indicated for surgical resection. Geriatr Gerontol Int 2017;17:189-201. [PMID: 26847184 DOI: 10.1111/ggi.12747] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
31 Bretagne M, Boudou-Rouquette P, Huillard O, Thomas-Schoemann A, Chahwakilian A, Orvoen G, Arrondeau J, Tlemsani C, Cessot A, Cabanes L, Blanchet B, Coriat R, Alexandre J, Goldwasser F. [Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management]. Bull Cancer 2016;103:259-72. [PMID: 26832420 DOI: 10.1016/j.bulcan.2015.10.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Yue H, Gou L, Tang Z, Liu Y, Liu S, Tang H. Construction of pH-responsive nanocarriers in combination with ferroptosis and chemotherapy for treatment of hepatocellular carcinoma. Cancer Nano 2022;13. [DOI: 10.1186/s12645-022-00111-4] [Reference Citation Analysis]
33 Nishikawa H, Takeda H, Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, Osaki Y, Izumi N; Japanese Red Cross Liver Study Group. Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan. J Cancer 2014;5:499-509. [PMID: 24963354 DOI: 10.7150/jca.9257] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
34 Brunot A, Le Sourd S, Pracht M, Edeline J. Hepatocellular carcinoma in elderly patients: challenges and solutions. J Hepatocell Carcinoma. 2016;3:9-18. [PMID: 27574587 DOI: 10.2147/jhc.s101448] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
35 Cabibbo G, Maida M, Cammà C, Craxì A. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age? Expert Rev Anticancer Ther. 2013;13:1355-1361. [PMID: 24224926 DOI: 10.1586/14737140.2013.859989] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
36 Arora SP, Liposits G, Caird S, Dunne RF, Moffat GT, Okonji D, Rodriquenz MG, Dua D, Dotan E. Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology. J Geriatr Oncol 2020;11:557-65. [PMID: 31704038 DOI: 10.1016/j.jgo.2019.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Chu KKW, Chok KSH. Is the treatment outcome of hepatocellular carcinoma inferior in elderly patients? World J Gastroenterol 2019; 25(27): 3563-3571 [PMID: 31367157 DOI: 10.3748/wjg.v25.i27.3563] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Choi GH, Han S, Shim JH, Ryu MH, Ryoo BY, Kang YK, Kim KM, Lim YS, Lee HC. Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice. Am J Clin Oncol 2017;40:167-74. [PMID: 25268070 DOI: 10.1097/COC.0000000000000132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
39 Du J, Mao Y, Liu M, Tie Y, Huang H, Zhao J, Xiang Z, Luo D. Dose age affect the efficacy of molecular targeted agents in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:102413-9. [PMID: 29254256 DOI: 10.18632/oncotarget.22061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Williet N, Clavel L, Bourmaud A, Verot C, Bouarioua N, Roblin X, Merle P, Phelip JM. Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma. Dig Liver Dis. 2017;49:1043-1049. [PMID: 28712860 DOI: 10.1016/j.dld.2017.06.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
41 Francini E, Mazzaroppi S, Fiaschi AI, Petrioli R, Laera L, Roviello G, Pira T, Pellicelli AM, Bianco V. Safety of Sorafenib Therapy in Elderly Adults with Advanced Hepatocellular Carcinoma. J Am Geriatr Soc 2014;62:2204-5. [DOI: 10.1111/jgs.13091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
42 Sun L, Lin Y, Wang G, Zhang L, Hu L, Lu Z. Correlation of zinc finger protein 2, a prognostic biomarker, with immune infiltrates in liver cancer. Biosci Rep 2021;41:BSR20203115. [PMID: 33439969 DOI: 10.1042/BSR20203115] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Golfieri R, Bilbao JI, Carpanese L, Cianni R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Cappelli A, Rodriguez M. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol. 2013;59:753-761. [PMID: 23707371 DOI: 10.1016/j.jhep.2013.05.025] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
44 Bruguera M. [Liver diseases in the elderly]. Gastroenterol Hepatol. 2014;37:535-543. [PMID: 24951302 DOI: 10.1016/j.gastrohep.2014.04.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
45 Macias RIR, Monte MJ, Serrano MA, González-Santiago JM, Martín-Arribas I, Simão AL, Castro RE, González-Gallego J, Mauriz JL, Marin JJG. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging (Albany NY) 2021;13:23416-34. [PMID: 34633987 DOI: 10.18632/aging.203620] [Reference Citation Analysis]
46 Hu H, Duan Z, Long X, Hertzanu Y, Tong X, Xu X, Shi H, Liu S, Yang Z. Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study. PLoS One 2015;10:e0117168. [PMID: 25689846 DOI: 10.1371/journal.pone.0117168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]